AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Britain's biggest drugmaker buying Seattle-based firm Icosavax, expanding vaccine and immune therapy business

AstraZeneca buys US vaccine company in $1.1bn deal

Icosavax

Vaccines specialist Icosavax Inc (NASDAQ: ICVX) is set to surge 45% on Tuesday after agreeing to be taken over by Anglo-Swedish pharma group AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) for $838 million cash up front, potentially rising to $1.1 billion.  Having closed at $10.51 yesterday, the stock jumped to $15.25 in pre-market trading this morning, above the offer price of $15.00 per share.

Icosavax surges 45% in pre-market trading as AstraZeneca agrees takeover

AstraZeneca agreed to acquire respiratory vaccine developer Icosavax in a cash deal expected to close in the first quarter of next year.

This Vaccine Stock Soars 46% After $1.1 Billion AstraZeneca Deal

AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common respiratory disease-causing viruses.

AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion

AstraZeneca has bought US biopharmaceutical company, Icosavax Inc, for up to $1.1 billion.  The Anglo-Swedish drugs maker said the deal will build on its expertise in respiratory syncytial virus (RSV), and strengthen its Vaccines & Immune Therapies late-stage pipeline with Icosavax's lead investigational vaccine candidate, IVX-A12.

AstraZeneca boosts RSV profile with $1.1bn Icosavax deal

Drugmaker AstraZeneca on Tuesday agreed to buy vaccine developer Icosavax in a deal valued at up to $1.1 billion to bolster its respiratory syncytial virus (RSV) vaccine portfolio.

AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 bln

AstraZeneca's stock is trading below its April 2022 highs, but the company is executing well and making the right moves to return and stay in growth mode. The company has managed the decline in COVID-19 revenues well, with strong performance in other product segments driving overall revenue growth. AstraZeneca has entered the obesity arena with a promising oral GLP-1 receptor agonist and has a deep and diverse pipeline of product candidates in various therapeutic areas.

AstraZeneca Is Feeling The Weight Of The Market In 2023

Amgen

Bristol-Myers

Gilead Sciences

Merck

Novo Nordisk

Novartis

Pfizer

Sanofi

This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.

6 Health Care Dividend Stocks To By Hand Over Fist

AstraZeneca is shelling out hundreds of millions to position itself to benefit from AI. Its competitors are following suit as the drug industry climbs onto the AI bandwagon.

AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?

AstraZeneca's pipeline is huge, and it's buying more assets to develop too. It's also making a major play to enter the digital healthcare space.

Is Now the Right Time to Buy AstraZeneca Stock?

Chevron

Jefferies Financial Group Inc

Republic Services

Southern Company

Simon Property Group

This integrated giant is safer for investors looking to get positioned in the energy sector, has backed up some, and now yields a strong 4.17% dividend.

Dividend Lovers Betting Big on 6 Goldman Sachs Top Conviction List Picks for 2024

Diageo

Lloyds Banking Group

Here's our daily round-up of what's been doing the rounds in the Square Mile.

AstraZeneca, Diageo, Lloyds & other UK Banks: What London's brokers had to say today

AstraZeneca PLC (LSE:AZN), the Anglo-Swedish pharmaceutical giant, stands as a quintessential example of a 'growth at a reasonable price' (GARP) investment opportunity, according to Bank of America. This strategy, which marries the principles of growth and value investing, seeks companies with consistent earnings growth that are not overvalued in the market.

AstraZeneca and the world according to GARP

JP Morgan has identified its top picks in the European pharmaceuticals and biotechnology sector for 2024, spotlighting large, mid, and small-cap companies poised for significant growth. Among its top tips were Novo Nordisk, AstraZeneca PLC (LSE:AZN), and Merck KGaA in the large-cap space, Argenx and DiaMonTech in mid-caps, and MorphoSys AG in small caps.

AstraZeneca and Novo Nordisk among the top picks of this top US bank - here's why

Absci Corp

Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday.

AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT

Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.

AstraZeneca (AZN) to Discontinue Two Studies on Lokelma

AstraZeneca PLC (LSE:AZN) has announced the discontinuation of two phase III trials, STABILIZE-CKD and DIALIZE-Outcomes, for its drug Lokelma (sodium zirconium cyclosilicate). This decision stems from logistical challenges, including extended timelines for patient enrolment and lower-than-expected occurrences of the conditions being studied.

AstraZeneca discontinues phase III trials

AstraZeneca on Friday said it would discontinue two late-stage trials looking at the potential benefits of its drug Lokelma in the management of hyperkalaemia across the cardiorenal spectrum.

AstraZeneca to scrap two trials on drug that curbs potassium

Apartment Income REIT Corp

Alexandria Real Estate Equities

COPT Defense Properties

Gaming and Leisure Properties

Healthcare Realty Trust Inc

Host Hotels & Resorts

Johnson Controls

LTC Properties

Banco Santander

Sabra Health Care

Telia Co AB

V.F.

Vici Properties

Telefonica Brasil

September-October, 2023, Barron's, Bloomberg, and Fortune analysts and reporters combined to list five sets of stocks sorted as “Recovery Bets.” Those five articles revealed 53 equities, with 42 paying-dividends. These recovery lists focus on financial services, healthcare, and real estate sectors by Barron's along with selected “change the world” stocks from Fortune and ten to watch from Bloomberg.

17 Ideal Pre-Crash Recovery December Divi-Dogs

SEATTLE , Nov. 30, 2023 /PRNewswire/ -- Presage Biosciences, a pioneering translational oncology company whose mission is to use CIVO and spatial molecular profiling to understand the complexity of drug response in the tumor microenvironment (TME), has entered into an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical company. According to the agreement, Presage's platform will be used by AstraZeneca in translational analysis to evaluate several investigational bispecific antibody combinations in samples taken from head and neck cancer patients.

Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present new clinical and real-world data in multiple hematological conditions at the 65th American Society of Hematology (ASH) Annual Meeting andExposition, December 9 to 12, 2023 in San Diego, CA. A total of 63 abstracts will feature 14 approved and potential new medicines across the Company's portfolio and pipeline including from Alexion, AstraZeneca's Rare Disease group, in chronic lymphocytic leukemia (CLL) and several types of lymphoma, p.

AstraZeneca advances scientific leadership in hematology at ASH 2023

AstraZeneca PLC (LSE:AZN) fell 0.9% as analysts at Jefferies trimmed estimates and argued that clarity on margins may be needed for further stock upside.  The broker, has a buy rating on the Anglo-Swedish drugs maker but lowered its price target to 12,500p from 13,000p, as well as cutting EPS estimates by up to 5%.

AstraZeneca needs margin clarity for further upside says Jefferies

Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Investors Heavily Search AstraZeneca PLC (AZN): Here is What You Need to Know

Amazon

NVIDIA

As Thanksgiving festivities wind down and markets remain closed for a two-day hiatus, investors find themselves in a brief respite from the relentless pace of trading.

Best 3 Thanksgiving stocks to buy

AstraZeneca could pay up to $2 billion to Eccogene for the rights to an obesity drug candidate. That candidate could give patients a safer option than those that are available in the market today.

Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant

News for AstraZeneca Stock (AZN)